NCT04585464 - A Study to Assess Safety, Tolerability, and PK of EDG-5506 in Healthy Volunteers and Becker Muscular Dystrophy Adults | Biotech Hunter

Enrollment

127

Participants

Timeline

Start Date

October 12, 2020

Primary Completion Date

November 15, 2021

Study Completion Date

December 27, 2021

Conditions

Healthy VolunteerBecker Muscular Dystrophy

Interventions

DRUG

EDG-5506

EDG-5506 is administered orally as a single dose or once daily

DRUG

Placebo

Placebo is administered orally as a single dose or once daily

Trial Locations (1)

Worldwide Clinical Trials, San Antonio